BioCentury
ARTICLE | Financial News

Amal raises $9.5M in first close of series B round

September 8, 2017 4:17 PM UTC

On Sept. 5, cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) raised €8 million ($9.5 million) in the first close of a series B round co-led by Boehringer Ingelheim Venture Fund, Bi...

BCIQ Company Profiles

Amal Therapeutics S.A.